Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01259063 |
| Title | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals, New York University, University of Hawaii |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |